Apex Therapeutics Announces FDA Acceptance of IND to Evaluate the Tolerability and Anti-Tumor Effects of APX3330

Indianapolis, IN – July 20, 2016 – ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced the acceptance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for clinical testing of the company’s lead drug candidate, APX3330 in pancreatic cancer. The initial portion of the phase 1 study will determine the maximum tolerated … Read more…